Biolinerx could mobilise interest in CXCR4 antagonism
A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
No knockout blow from Rubius
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
